Traditional medicines are sold to foreign employers? | 100% FDI allowed.
In 1995, WR Grace of Colombia applied for a patent for its “Neemix” pesticide at the European Patent Office (EPO).
Neemix is a biological pesticide made from neem. Natural method product. The company said in its application that it would protect crops from as many as 200 pesticides. The company claimed the patent for such a compound.
The only way to get this application approved is for the company not to use neem in any compound as a pesticide on EU land.
After efforts by various Indian and multinational service organizations, the European Patent Office (EPO) rejected the application as Prior Existing Knowledge of Indians.
On, who knows who faced this case? Ayya Nammalavar who was part of the group led by Vandana Siva. As a result of a series of attempts by some organizations, a massive trade attack was halted.
Today, the Indian government has paved the way for such a commercial invasion. Yes. The Central Government has opened 100% Foreign Direct Investment (FDI) in AYUSH (Ayurveda, Yoga & Naturopathy, Unani, Siddha and Homeopathy Medicine) India, the world’s second largest traditional export market.
Indian Prior Knowledge (Prior Existing Knowledge) is now the world’s marketable product.
Corona turned the deadly period into a favourable environment for China’s traditional medicine (Chinese Traditional Medicine (TCM)). As of last March, 92.5% of patients had been treated with traditional Chinese medicine, the report said.
This corona period was a golden age for Chinese traditional medicine. This corona disaster has helped as an opportunity to prove its uniqueness.
If so, does this also apply to the thousands of years old Indian Ayurveda, Unani, Naturopathy, Siddha Medicine, Homeopathy (AYUSH)?
But the situation is reversed. The government does not have enough scientific research to recognize even “capsicum drinking water” as a medicine for common infections.
Why study traditional medicine? Diseases are new. Today’s scientific development and comprehensive knowledge of physiology have given us new clarity about medicine.
Although a topic that needs to be described in more detail in many articles, Evidence Based Medicine (EBM), today’s world community has moved to the place of “research based on data.”
That is, it is unlikely that the corona will shrink if you grind and consume the arali seeds. Proper studies are needed for that. At the very least, there is a need for systematic research into what “enhances immunity”.
Chinese Traditional Medicine (TCM) has conducted many such studies and has maintained a unique position in the global medical market. As such, AYUSH is the government agency created to scientifically gain recognition for Indian traditional medicine in the commercial world.
But, it is unfortunate that the studies here are not yet dense enough to take us to worldviews. However, by the way, India is today the second largest export market for traditional medicine in the world. According to AYUSH, nearly 1,500 pharmaceutical products are nearing completion.
Even more surprising is the fact that the Indian market value of AYUSH medicine is US $ 10 billion. Yet why do we ask, “Why not talk about a complete AYUSH Complete Cure package treatment for Corona?” The question is unanswered.
It is in this context that, as on March 18, AYUSH has opened up 74% of spontaneous FDI (without government intervention) to the market under Make In India 2.0. Government approval is required for investments above 74 per cent. Thus, “Indian Traditional Medicine” has become a market for 100 percent foreign direct investment.
That is, you, and I even can get foreign investment in a formal research environment and do extensive research on Indian Prior Existing traditional knowledge.
OK. What’s wrong? Is it a kind of multiplication of knowledge? Opportunity itself? No. The foreign domination that had formerly existed over Indian traditional knowledge, is today fully acquired.
The AYUSH market is not just about drugs. Foreign investment in hospitals, medical equipment, clinical trials, medical tourism, and medical insurance will no longer be a field.
The way to a comprehensive world-class study is to be able to taste the patent of Indian medical knowledge by a foreign company.
What’s wrong? A small analysis of patents is needed to fully understand this. There is no such thing as patent law in India. The patent, however, holds the world market in its iron hands.
The World Trade Organization (WTO) is the mother of these drafts of foreign direct investment. That is, the Chamber of Commerce will determine the legal reforms to be adopted by developing countries that have embraced globalization. Thus, the TRIPS Agreement is the arrow that has been fired at the Chamber of Commerce and Development.
Simply put, the essence of TRIPS is to “provide adequate ‘intellectual property protection’ with respect to investment in world trade.”
That is, the council’s definition of a drug as “patentable” is “exclusive rights for sale” to a company that has fully explored its uses.
This is also the definition of “patent” in the trade language of many countries of the world.
Accordingly, India adopted the Trade-Related Aspects of Intellectual Property Rights (TRIPS) Agreement in 1995 and made significant changes to the Indian Patent Act. This way, more laws are guaranteed to be tightened in the coming times.
Realizing the seriousness of this, Vandana Siva and Nammazhvar faced the case that day. If that patent is granted, the vision is that tomorrow, through TRIPS, any company that invests directly in agriculture will be able to prevent us from picking up neem on the land.
Now, do you understand the problem with the opening of the AYUSH market? Having fought for the rights of a street tree, we have spread the market knowledge of the legacy of thousands of plants.
The Indian medical market is divided into two categories. One is Modern Medicine and the other is AYUSH. In the AYUSH category, it should be realized that complete foreign investment involves many future issues. Traditional knowledge is not something that is fully taken up by India and taken over by foreign companies.
In the global flow of growth, the reality is that we need to make some concessions to sustain ourselves. But it is not a development that distorts our priorities in multinational corporations as needed.
Before we open our traditional knowledge to the hands of multinational machinery, we must clearly define our boundaries on patents and intellectual property.
Otherwise, there can be no doubt that within a hundred years the genetics will be completely swallowed up and sold to us as medicine in bottles.
The sole purpose of this article is to “create a full-fledged discussion on this in the Indian traditional knowledge base”.
W. R. Grace & Co. And the Neemix Patent (a)
India wins landmark patent battle
6 effective traditional Chinese medicines for COVID-19
AYUSH industry may create 26 mn jobs by 2020: Suresh Prabhu
TRIPS and pharmaceutical patents